IRVINE, Calif., July 18, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Mattel, Inc. (“Mattel” or the “Company”) (Nasdaq:MAT). Investors who purchased or otherwise acquired shares between October 20, 2016 and April 20, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the August 28, 2017 lead plaintiff motion deadline.
If you purchased Mattel shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the Complaint, during the Class Period, Mattel made false and/or misleading statements, and/or failed to disclose adverse information, including that the Company’s retail customers had high levels of unsold Mattel products, thus exposing it to the heightened risk that it would have to issue its retailers financial concessions to remove the excess inventory, and that it would experience slower sales growth in future periods. On April 20, 2017, Mattel announced its first quarter 2017 financial results, reporting declines for its worldwide net sales and gross margins on a year-over-year basis, and an increase of more than 158% in its operating loss. These results were well below Wall Street consensus estimates. When this news was announced, shares of Mattel fell in value materially, which caused investors harm according to the Complaint.
If you want to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
FDA Approves Mitapivat for Anemia in Thalassemia Patients 



